
Network News

The aim of the project is to use special quantitative MRI to visualize early changes in the intervertebral disc and enable timely treatment. Ultrashort echo time (UTE) MRI opens up completely new approaches to preventive imaging that are difficult or impossible to achieve with conventional MRI methods. Full text in German below. DFG fördert Heidelberger […]
read more
aimed analytics secures six-digit first funding and acquires ValueData GmbH
aimed analytics GmbH has successfully closed its first funding round, raising a six-digit investment. At the same time, the company has completed the acquisition of ValueData GmbH, further strengthening its position as a pioneer in AI-driven biomedical data analytics. “Our mission is clear: to shape the future of medicine through the power of data analytics. […]
read more
After EMBL: Umlaut.bio and its potential role in drug development
Alumnus Bastian Linder discusses the origin of this start-up and how a tRNA mechanism is helping scientists understand the importance and use of various RNA modifications as they pertain to disease. With just two dots above a letter, the German umlaut can instantly change a word’s pronunciation, its quantity (singular to plural), or even its […]
read more
ERC Awards Four Starting Grants to Universität Heidelberg
European Research Council funds groundbreaking projects by early-career researchers The European Research Council is awarding four valuable grants to Heidelberg University. These ERC Starting Grants go to researchers in early stages of their career who want to carry out groundbreaking research with ERC funding. They include Dr Michael Gerlt, who will do research at the […]
read more
European Commission Grants Approval of Ogsiveo
Merck announced that the European Commission granted approval for Ogsiveo for the treatment of adults with desmoid tumors. 18 Aug 2025 | Darmstadt, Germany Merck, a leading science and technology company, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing […]
read more
1.2 million euros in funding for the production of “gene taxis”
The Dietmar Hopp Foundation is supporting the establishment of an experimental production unit for gene therapies for the heart at Heidelberg University’s Medical Faculty, in the Department of Cardiology, Angiology, and Pneumology at Heidelberg University Hospital (UKHD). The new production capacities for therapeutic viruses, the “gene taxis” to the diseased heart, strengthen the pioneering role […]
read more
BioMed X and Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 receptor agonists via BioMed X’s global talent sourcing and incubation model. Heidelberg, Germany, August 19th, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Novo Nordisk, […]
read more
International Research Award in Dentistry goes to Heidelberg Institute of Global Health
A great honor for Professor Dr. Dr. Stefan Listl from the Medical Faculty of Heidelberg University: The International Association for Dental, Oral, and Craniofacial Research (IADR) honored him at its annual meeting with the prestigious Distinguished Scientist Award in the field of social science, epidemiology, and health services research. This award is one of the […]
read more
AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate
SEATTLE AND HEIDELBERG – July 29, 2025 – AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO’s Heidelberg facility. Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which […]
read more